Observations placeholder
Samsca
Identifier
020017
Type of Spiritual Experience
Background
A description of the experience
Tolvaptan (INN, trade names Samsca and Jinarc) is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, under the trade name Samsca under the trade name Tolsama & Tolvat and under the brand name Resodim.
Tolvaptan was also in fast-track clinical trials for polycystic kidney disease. In a 2004 trial, tolvaptan, when administered with traditional diuretics, was noted to increase excretion of excess fluids and improve blood sodium levels in patients with heart failure without producing side effects such as hypotension (low blood pressure) or hypokalemia (decreased blood levels of potassium) and without having an adverse effect on kidney function.
On Feb, 7, 2016: 795 people reported to have side effects when taking Samsca. Among them, 3 people (0.38%) have Hallucination.
Time on Samsca when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Jan, 26, 2016: 795 people reported to have side effects when taking Samsca. Among them, 21 people (2.64%) have Death.
Time on Samsca when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 87.50% | 12.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |